All In Biotech

Drug Trial Radar · NCT00079274

Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer

A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients With Stage III Colon Cancer

Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,397 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,397

Actual

Start

Feb 2004

Primary completion

Nov 2012

Study completion Nov 2012

Sponsor

Sponsor type
NIH
Collaborators
Eastern Cooperative Oncology Group
First posted
Mar 10, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial was originally designed to compare three different combination chemotherapy regimens to see how well they work. As of September 1, 2004, the study was expanded to a total of 6 arms (the original 3 arms (A, B, C) and 3 additional arms which were the same as the first 3 but with cetuximab) in treating patients who have undergone surgery for stage III colon cancer. Drugs used in chemotherapy, such as irinotecan hydrochloride, fluorouracil, leucovorin calcium, and oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining more than one chemotherapy drug with monoclonal antibody therapy and giving them after surgery may kill any remaining tumor cells. It was not known at the time this study was developed which combination chemotherapy regimen is more effective after surgery in treating colon cancer. This study had several key changes, based on the results of other phase III trials. As of 6/1/2005, patients no longer received irinotecan on this study and treatment arms B, C, E, and F were discontinued. Patients on arms B and C crossed to arm A. Patients on arms E and F crossed to arm D. Patients on arms C and F who had not gotten to irinotecan continued on arms A and D, respectively. As of 8/18/2008, pre-screening for Kirsten rat sarcoma (KRAS) status was added with mutant KRAS (or KRAS not evaluable) patients put on arm G and wild-type KRAS patients randomized between arm A and arm D. Patients on arm G were treated per physician discretion and followed for disease and survival status. KRAS was determined in a central laboratory and was process for all patients on this study. The primary endpoint of this study was modified on 8/18/2008 to focus on patients having wild-type KRAS tumors. All modifications were approved by the Central Institution Review Board, local Institutional Review Boards, NCI, and the NCCTG Data Safety Monitoring Board.

Conditions

  • Adenocarcinoma of the Colon
  • Stage III Colon Cancer

Interventions

  • irinotecan hydrochlorideDrug

    Given IV

  • oxaliplatinDrug

    Given IV

  • leucovorin calciumDrug

    Given IV

  • fluorouracilDrug

    Given IV

  • cetuximabBiological

    Given IV

  • Locally Directed TherapyDrug

    Patients determined to have mutated KRAS (or KRAS not evaluable) will be assigned to an event monitoring arm in which adjuvant therapy will be determined and assigned by the treating oncologist. The determination of the type of therapy, duration of treatment, and dose modification will be the responsibility of the treating oncologists.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free Survival (Arms A and D: Wild-type KRAS Patients)Time frame: At 3 years

Locations

894 sites in 3 countries. Site status is shown where the registry gives one.

  • Northeast Alabama Regional Medical Center

    Anniston, Alabama

  • Clearview Cancer Institute

    Huntsville, Alabama

  • Mobile Infirmary Medical Center

    Mobile, Alabama

  • Providence Hospital

    Mobile, Alabama

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Banner Thunderbird Medical Center

    Glendale, Arizona

  • Banner Desert Medical Center

    Mesa, Arizona

  • Banner Baywood Medical Center

    Mesa, Arizona

  • Banner Good Samaritan Medical Center

    Phoenix, Arizona

  • Western Regional CCOP

    Phoenix, Arizona

  • Phoenix Indian Medical Center

    Phoenix, Arizona

  • Scottsdale Healthcare

    Scottsdale, Arizona

  • Mayo Clinic in Arizona

    Scottsdale, Arizona

  • Highlands Oncology Group-Bentonville

    Bentonville, Arkansas

  • Saint Edward Mercy Medical Center

    Fort Smith, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Veteran's Administration Medical Center

    Little Rock, Arkansas

  • Alta Bates Medical Center-Herrick Campus

    Berkeley, California

  • Providence Saint Joseph Medical Center

    Burbank, California

  • Mills - Peninsula Hospitals

    Burlingame, California

  • East Bay Radiation Oncology Center

    Castro Valley, California

  • Eden Hospital Medical Center

    Castro Valley, California

  • Valley Medical Oncology Consultants-Castro Valley

    Castro Valley, California

  • City of Hope

    Duarte, California

  • Northbay Cancer Center

    Fairfield, California

  • Kaiser Permanente, Fremont

    Fremont, California

  • Valley Medical Oncology Consultants-Fremont

    Fremont, California

  • California Cancer Center - North Fresno

    Fresno, California

  • Cancer Care Associates

    Fresno, California

  • California Cancer Care - Greenbrae

    Greenbrae, California

  • Sutter Health Western Division Cancer Research Group

    Greenbrae, California

  • Kaiser Permanente, Hayward

    Hayward, California

  • Saint Rose Hospital

    Hayward, California

  • Loma Linda University Medical Center

    Loma Linda, California

  • University of Southern California

    Los Angeles, California

  • Contra Costa Regional Medical Center

    Martinez, California

  • Fremont - Rideout Cancer Center

    Marysville, California

  • Memorial Medical Center

    Modesto, California

  • Community Hospital of Monterey Peninsula

    Monterey, California

  • El Camino Hospital

    Mountain View, California

Showing 40 of 894 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.